KEROS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.78 USD | -4.29% |
|
-3.29% | +40.29% |
| Mar. 19 | Morphic Holding Names Simon Cooper as Chief Medical Officer | MT |
| Mar. 15 | Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug | MT |
Financials (USD)
| Sales 2024 * | 5.67M | Sales 2025 * | 22.22K | Capitalization | 2.01B |
|---|---|---|---|---|---|
| Net income 2024 * | -175M | Net income 2025 * | -200M | EV / Sales 2024 * | 301 x |
| Net cash position 2024 * | 304M | Net cash position 2025 * | 123M | EV / Sales 2025 * | 85,006 x |
| P/E ratio 2024 * |
-10.7
x | P/E ratio 2025 * |
-10.3
x | Employees | 136 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.64% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -4.29% | ||
| 1 week | -3.29% | ||
| Current month | -15.74% | ||
| 1 month | -15.32% | ||
| 3 months | +1.83% | ||
| 6 months | +96.82% | ||
| Current year | +40.29% |
1 week
55.54
61.33
1 month
55.5467.49
Current year
39.0073.00
1 year
27.0273.00
3 years
24.3873.00
5 years
19.1088.80
10 years
19.1088.80
| Managers | Title | Age | Since |
|---|---|---|---|
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 15-11-30 |
Keith Regnante
DFI | Director of Finance/CFO | 54 | 20-01-31 |
Jennifer Lachey
CTO | Chief Tech/Sci/R&D Officer | 51 | 16-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 20-12-16 |
Carl Gordon
CHM | Chairman | 59 | 20-02-29 |
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 15-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.06% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 55.78 | -4.29% | 275,096 |
| 24-04-19 | 58.28 | -1.14% | 348,567 |
| 24-04-18 | 58.95 | -0.54% | 296,534 |
| 24-04-17 | 59.27 | +2.19% | 397,880 |
| 24-04-16 | 58 | +0.55% | 196,607 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotes
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
55.78
USD
Average target price
88.11
USD
Spread / Average Target
+57.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.29% | 2.01B | |
| +2.49% | 96.73B | |
| -0.38% | 21.31B | |
| -16.61% | 21.21B | |
| -5.29% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- KROS Stock
